Match tier
Confirmed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
M
Meagan B. Myers
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Research Biologist
Also affiliated: United States Food and Drug Administration (2003–2025); University of the Witwatersrand (2008); Truman Medical Center (1990); Arkansas Department of Agriculture (2003)
Faculty Researcher
20 h-index
47 pubs
972 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Meagan B. Myers is a Research Biologist at the National Center for Toxicological Research. Her work focuses on genotoxicity assessment and the development of advanced sequencing technologies for evaluating DNA mutations. Myers has published research on error-corrected next-generation sequencing, exploring its potential and challenges for genotoxicity testing and cancer risk assessment. Her publications also address the measurement of cancer driver mutations in animal models, correlating these findings with spontaneous neoplasia incidence. Additionally, she has contributed to consensus recommendations for evaluating teratoma formation risk in cell therapy products and has investigated the use of mutation as a toxicological endpoint for risk assessment.
Myers' research employs techniques such as polymerase chain reaction and duplex sequencing for mutation quantification. Her scholarship metrics include an h-index of 19, with 47 total publications and 957 total citations. Key collaborators include Barbara L. Parsons, Robert H. Heflich, Page B. McKinzie, and Kelly L. Harris, all from the National Center for Toxicological Research, with whom she shares multiple publications.
Metrics
- h-index: 20
- Publications: 47
- Citations: 972
Selected Publications
-
Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans (2026)
-
Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing (2025)
-
Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute’s International Cell Therapy Committee (2025)
-
CarcSeq detection of lorcaserin-induced clonal expansion of<i>Pik3ca</i>H1047R mutants in rat mammary tissue (2024)
-
<scp>Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing</scp> ( <scp>IWGT</scp> ) (2024)
-
Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment (2023)
-
A Brief Practical Guide to PCR (2023)
-
Clinical Applications of Nucleic Acid Amplification (2023)
-
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing (2023)
-
Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia (2021)
-
Quantification of cancer driver mutations in human breast and lung <scp>DNA</scp> using targeted, error‐corrected <scp>CarcSeq</scp> (2020)
-
Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids (2020)
-
ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations (2020)
-
Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk (2019)
-
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology (2019)
Collaboration Network
Top Collaborators
Barbara L. Parsons
United States Food and Drug Administration
6 shared publications
In database
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- CarcSeq detection of lorcaserin-induced clonal expansion of<i>Pik3ca</i>H1047R mutants in rat mammary tissue
- <scp>Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing</scp> (<scp>IWGT</scp>)
Showing 5 of 6 shared publications
Connie L. Chen
Health and Environmental Sciences Institute (US)
4 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute’s International Cell Therapy Committee
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Francesco Marchetti
Health Canada (CA)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
George R. Douglas
Health Canada (CA)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- <scp>Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing</scp> (<scp>IWGT</scp>)
Robert H. Heflich
National Center for Toxicological Research
3 shared publications
In database
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- <scp>Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing</scp> (<scp>IWGT</scp>)
Anthony M. Lynch
Genetic Technologies (Australia) (AU)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- <scp>Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing</scp> (<scp>IWGT</scp>)
Jesse J. Salk
Blaze Bioscience (United States) (US)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Raja S. Settivari
Corteva (United States) (US)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Stephanie L. Smith‐Roe
Triangle (US)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Carole L. Yauk
University of Ottawa (CA)
3 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing
Renato Cardoso
2 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
Joanne Elloway
AstraZeneca (United Kingdom) (GB)
2 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
Patricia A. Escobar
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
2 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
Tod A. Harper
Amgen (United States) (US)
2 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
Darren Kidd
2 shared publications
- Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
- Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
Similar Researchers
Based on overlapping research topics
Ji‐Eun Seo
National Center for Toxicological Research
Carcinogens and Genotoxicity Assessment
Molecular Biology Techniques and Applications
Pharmacological Effects and Toxicity Studies
S A Montoya Guerrero
National Center for Toxicological Research
Carcinogens and Genotoxicity Assessment
Molecular Biology Techniques and Applications
Pharmacological Effects and Toxicity Studies
Page B. McKinzie
National Center for Toxicological Research
Carcinogens and Genotoxicity Assessment
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
Robert H. Heflich
National Center for Toxicological Research
Carcinogens and Genotoxicity Assessment
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
Vasily N. Dobrovolsky
National Center for Toxicological Research
Carcinogens and Genotoxicity Assessment
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
Jennifer Faske
National Center for Toxicological Research
Carcinogens and Genotoxicity Assessment
Genomics and Phylogenetic Studies
Pharmacological Effects and Toxicity Studies